Shares of Targanta Therapeutics Corp. plummeted 40 percent Tuesday after the Cambridge, Mass.-based firm said it received a complete response letter from the FDA asking for another study of oritavancin, an investigational antibiotic being developed for the treatment of complicated skin and skin structure infections (cSSSIs). (BioWorld Today) Read More